Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsNASALStandard

ATZUMI

DIHYDROERGOTAMINE MESYLATE

Standard Dose
EQ 5.2MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ATZUMI is listed in Drugs@FDA under application 217901 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient DIHYDROERGOTAMINE MESYLATE Form and strength POWDER;NASAL - EQ 5.2MG BASE Sponsor SATSUMA PHARMS Submission history Latest submission status date: 2025-04-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview ATZUMI is listed in Drugs@FDA under application 217901 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient DIHYDROERGOTAMINE MESYLATE Form and strength POWDER;NASAL - EQ 5.2MG BASE Sponsor SATSUMA PHARMS Submission history Latest submission status date: 2025-04-30 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.